check_circleStudy Completed
Bayer Identifier:
10954
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Dose-escalating Phase I study to define the safety profile, pharmacokinetics, pharmacodynamics and tumor response profile of BAY 43-9006 in combination with oxaliplatin chemotherapy in patients
Trial purpose
Key Participants Requirements
Sex
N/AAge
32 - 79 YearsTrial summary
Enrollment Goal
37Trial Dates
November 2002 - December 2007Phase
Phase 1Could I Receive a placebo
N/AProducts
Nexavar (Sorafenib, BAY43-9006)Accepts Healthy Volunteer
NoTrial design
Trial Type
InterventionalIntervention Type
N/ATrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A